Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
STVN Stock Forecast 2026-2027
$18.90
Current Price
$5.41B
Market Cap
Buy 9
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to STVN Price Targets
+69.3%
To High Target of $32.00
+32.3%
To Median Target of $25.00
-7.4%
To Low Target of $17.50
STVN Price Momentum
-4.3%
1 Week Change
+14.5%
1 Month Change
-26.0%
1 Year Change
-6.1%
Year-to-Date Change
-32.5%
From 52W High of $28.00
+46.6%
From 52W Low of $12.89
📊 TOP ANALYST CALLS
Did STVN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Stevanato is one of their latest high-conviction picks.
Latest STVN Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, STVN has a bullish consensus with a median price target of $25.00 (ranging from $17.50 to $32.00). The overall analyst rating is Strong Buy (8.9/10). Currently trading at $18.90, the median forecast implies a 32.3% upside. This outlook is supported by 9 Buy, 2 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
STVN Analyst Ratings
9
Buy
2
Hold
0
Sell
STVN Price Target Range
Low
$17.50
Average
$25.00
High
$32.00
Current: $18.90
Latest STVN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for STVN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 16, 2026 | TD Cowen | Buy | Initiates | $25.00 | |
| Jun 2, 2026 | Wolfe Research | Mike Polark | Outperform | Assumes | $21.00 |
| Mar 6, 2026 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Mar 5, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Mar 5, 2026 | Keybanc | Overweight | Maintains | $N/A | |
| Dec 2, 2025 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Nov 11, 2025 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Mar 7, 2025 | UBS | Neutral | Maintains | $N/A | |
| Dec 13, 2024 | B of A Securities | Buy | Maintains | $N/A | |
| Dec 13, 2024 | Wolfe Research | Outperform | Initiates | $N/A | |
| Dec 3, 2024 | Morgan Stanley | Tejas Savant | Equal-Weight | Assumes | $23.00 |
| Aug 7, 2024 | Citigroup | Buy | Maintains | $N/A | |
| Jul 15, 2024 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Apr 22, 2024 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Mar 25, 2024 | Stephens & Co. | Overweight | Reiterates | $N/A | |
| Nov 1, 2023 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Nov 1, 2023 | Jefferies | Hold | Downgrade | $N/A | |
| Sep 26, 2023 | Stephens & Co. | Overweight | Initiates | $N/A | |
| Sep 19, 2023 | CJS Securities | Market Outperform | Initiates | $N/A | |
| Aug 30, 2023 | Keybanc | Overweight | Maintains | $N/A |
Stevanato Group S.p.A. (STVN) Competitors
The following stocks are similar to Stevanato based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
STVN
Stevanato
mkt cap
5.35B
Stevanato Group S.p.A. (STVN) Financial Data
Stevanato Group S.p.A. has a market capitalization of $5.41B with a P/E ratio of 34.7x. The company generates $1.38B in trailing twelve-month revenue with a 11.7% profit margin.
Revenue growth is +6.6% quarter-over-quarter, while maintaining an operating margin of +14.2% and return on equity of +9.6%.
Valuation Metrics
Market Cap
$5.41B
Enterprise Value
$6.56B
P/E Ratio
34.7x
PEG Ratio
24.1x
Price/Sales
4.6x
Growth & Margins
Revenue Growth (YoY)
+6.6%
Gross Margin
+27.5%
Operating Margin
+14.2%
Net Margin
+11.7%
EPS Growth
+5.7%
Financial Health
Cash/Price Ratio
+2.2%
Current Ratio
1.6x
Debt/Equity
29.4x
ROE
+9.6%
ROA
+5.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Stevanato Group S.p.A. (STVN) Business Model
About Stevanato Group S.p.A.
What They Do
Provides drug containment and delivery solutions.
Business Model
The company operates by offering a comprehensive range of products and services that cater to the pharmaceutical, biotechnology, and life sciences sectors. It generates revenue through its Biopharmaceutical and Diagnostic Solutions segment, which supplies essential packaging and delivery components, as well as its Engineering segment, which provides specialized equipment and services to ensure compliance and product quality.
Additional Information
Established in 1949 and headquartered in Piombino Dese, Italy, the company has a strong focus on technological innovation and maintains a global presence with production sites in various countries. Stevanato Group S.p.A. is well-positioned to serve key players in the biopharmaceutical industry, offering integrated solutions that span the entire drug life cycle.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
5,521
CEO
Mr. Franco Stevanato
Country
Italy
IPO Year
2021
Website
www.stevanatogroup.comStevanato Group S.p.A. (STVN) Latest News & Analysis
Latest News
Quick Summary
Stevanato Group is rated a Buy due to strong Q1 results and growth in High-Value Solutions, now 47% of sales. Engineering segment slowdown is linked to timing, not demand issues.
Why It Matters
Stevanato Group's strong Q1 results and growth in High-Value Solutions enhance investor confidence, while improved profitability signals resilience despite Engineering segment challenges.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Stevanato Group S.p.A. (NYSE: STVN) launched Deora™, a new pen injector platform for incretin-based therapies, supporting various drug development programs.
Why It Matters
Stevanato's launch of the Deora™ pen injector could enhance its market position in drug delivery, potentially increasing revenue from the growing diabetes therapy sector and attracting investor interest.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Stevanato's shares are down this year but are gaining from increased demand for GLP-1 injectables.
Why It Matters
Stevanato's growth from GLP-1 injectables indicates potential for recovery or gains, contrasting with overall market declines, which could attract investors seeking opportunities.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Investors should closely monitor STVN stock due to recent activity in the options market.
Why It Matters
Increased options market activity for STVN stock may indicate heightened investor interest or volatility, potentially foreshadowing price movements and trading opportunities.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
Stevanato Group S.p.A. (NYSE: STVN) announced that all resolutions at its Shareholders' Meeting on May 26, 2026, were approved.
Why It Matters
The approval of resolutions at Stevanato Group's shareholder meeting signals strong governance and strategic direction, potentially boosting investor confidence and impacting stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Stevanato Group S.p.A. (STVN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
2 months ago
Quick Summary
Stevanato Group S.p.A. (STVN) presented at the Bank of America Global Healthcare Conference, discussing its strategies and outlook for 2026.
Why It Matters
Stevanato Group's presentation at a major healthcare conference can signal growth prospects and investor interest, impacting stock performance and market confidence in the company.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About STVN Stock
What is Stevanato Group S.p.A.'s (STVN) stock forecast for 2027?
Based on our analysis of 3 Wall Street analysts, Stevanato Group S.p.A. (STVN) has a median price target of $25.00. The highest price target is $32.00 and the lowest is $17.50.
Is STVN stock a good investment in 2027?
According to current analyst ratings, STVN has 9 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $18.90. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for STVN stock?
Wall Street analysts predict STVN stock could reach $25.00 in the next 12 months. This represents a 32.3% increase from the current price of $18.90. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Stevanato Group S.p.A.'s business model?
The company operates by offering a comprehensive range of products and services that cater to the pharmaceutical, biotechnology, and life sciences sectors. It generates revenue through its Biopharmaceutical and Diagnostic Solutions segment, which supplies essential packaging and delivery components, as well as its Engineering segment, which provides specialized equipment and services to ensure compliance and product quality.
What is the highest forecasted price for STVN Stevanato Group S.p.A.?
The highest price target for STVN is $32.00 from at , which represents a 69.3% increase from the current price of $18.90.
What is the lowest forecasted price for STVN Stevanato Group S.p.A.?
The lowest price target for STVN is $17.50 from at , which represents a -7.4% decrease from the current price of $18.90.
What is the overall STVN consensus from analysts for Stevanato Group S.p.A.?
The overall analyst consensus for STVN is bullish. Out of 3 Wall Street analysts, 9 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $25.00.
How accurate are STVN stock price projections?
Stock price projections, including those for Stevanato Group S.p.A., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 3:06 AM UTC